Vistin Pharma Logo

Vistin Pharma

A leading global producer of Metformin Hydrochloride for the global healthcare market.

VISTN | OL

Overview

Corporate Details

ISIN(s):
NO0010734122
LEI:
5967007LIEEXZXFQY092
Country:
Norway
Address:
Postboks 6735 Etterstad, 0609 Oslo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Vistin Pharma is a specialized pharmaceutical company and a leading global producer of Metformin Hydrochloride, the standard first-line treatment for Type 2 diabetes. The company operates as a pure-play metformin supplier, producing both Active Pharmaceutical Ingredients (API) and Direct Compressible (DC) grades for the global healthcare market. As a dedicated European manufacturer, Vistin Pharma is positioned to supply a significant portion of the world's demand for this essential medicine, with a focus on high-quality and sustainable production.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-31 07:40
Investor Presentation
Vistin Pharma ASA: Third quarter and YTD 2025 financial results - Attachment: V…
English 1.7 MB
2025-10-31 07:40
Quarterly Report
Vistin Pharma ASA: Third quarter and YTD 2025 financial results - Attachment: V…
English 1.5 MB
2025-10-31 07:40
Earnings Release
Vistin Pharma ASA: Third quarter and YTD 2025 financial results
English 2.2 KB
2025-10-24 10:00
Report Publication Announcement
Vistin Pharma ASA: Invitation to Q3 2025 conference call
English 2.6 KB
2025-08-15 08:00
Interim Report
Vistin Pharma ASA: Second quarter and YTD 2025 financial results - Attachment: …
English 1.6 MB
2025-08-15 08:00
Investor Presentation
Vistin Pharma ASA: Second quarter and YTD 2025 financial results - Attachment: …
English 1.9 MB
2025-08-15 08:00
Earnings Release
Vistin Pharma ASA: Second quarter and YTD 2025 financial results
English 2.1 KB
2025-08-08 10:00
Regulatory News Service
Vistin Pharma ASA: Invitation to Q2 2025 conference call
English 1.6 KB
2025-06-04 08:00
Notice of Dividend Amount
Ex dividend NOK 1.25 today
English 330 bytes
2025-05-23 09:22
Report Publication Announcement
Financial calendar
English 464 bytes
2025-05-23 09:22
Report Publication Announcement
Finansiell kalender
Norwegian 448 bytes
2025-05-22 12:59
Post-Annual General Meeting Information
Vistin Pharma ASA: Minutes from the annual general meeting 2025
English 897.7 KB
2025-05-22 12:59
Post-Annual General Meeting Information
Vistin Pharma ASA: Minutes from the annual general meeting 2025
English 736 bytes
2025-05-22 09:56
Proxy Solicitation & Information Statement
Disclosure of voting rights at AGM in Vistin Pharma ASA
English 963 bytes
2025-05-07 13:30
Board/Management Information
Vistin Pharma ASA (VISTN): Update from the Election Committee
English 1.3 KB

Automate Your Workflow. Get a real-time feed of all Vistin Pharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vistin Pharma

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vistin Pharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NEOGEN CORP Logo
Provides diagnostic tests and genomics services for food, animal, and agricultural safety.
United States of America
NEOG
NEOGENOMICS INC Logo
Provides precision oncology testing for cancer diagnostics, therapy guidance, and research.
United States of America
NEO
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America
950220
NEONC TECHNOLOGIES HOLDINGS, INC. Logo
Developing intranasal drug delivery to treat brain cancer & CNS diseases by crossing the BBB.
United States of America
NTHI
Neumora Therapeutics, Inc. Logo
Developing data-driven precision medicines for neuropsychiatric and neurodegenerative disorders.
United States of America
NMRA
Neuphoria Therapeutics Inc. Logo
Develops novel ion channel modulators for treating neuropsychiatric disorders like anxiety & PTSD.
United States of America
NEUP
NEUROCRINE BIOSCIENCES INC Logo
Develops therapies for neurological, neuroendocrine, and neuropsychiatric disorders.
United States of America
NBIX
Neurogene Inc. Logo
Developing genetic medicines using gene therapy for rare and devastating neurological diseases.
United States of America
NGNE
NeuroSense Therapeutics Ltd. Logo
Developing combination therapies for neurodegenerative diseases, with a focus on ALS.
United States of America
NRSN
NewAmsterdam Pharma Co N.V. Logo
Developing oral LDL-lowering therapies for high-risk cardiovascular disease patients.
United States of America
NAMS

Talk to a Data Expert

Have a question? We'll get back to you promptly.